- Home
- BIIB vs FWONA Comparison
BIIB vs FWONA Comparison
Compare BIIB & FWONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FWONA
- Stock Information
- Founded
- BIIB 1978
- FWONA 1950
- Country
- BIIB United States
- FWONA United States
- Employees
- BIIB N/A
- FWONA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FWONA Broadcasting
- Sector
- BIIB Health Care
- FWONA Industrials
- Exchange
- BIIB Nasdaq
- FWONA Nasdaq
- Market Cap
- BIIB 18.7B
- FWONA 22.3B
- IPO Year
- BIIB 1991
- FWONA N/A
- Fundamental
- Price
- BIIB $132.22
- FWONA $90.12
- Analyst Decision
- BIIB Buy
- FWONA Strong Buy
- Analyst Count
- BIIB 27
- FWONA 2
- Target Price
- BIIB $188.09
- FWONA $106.00
- AVG Volume (30 Days)
- BIIB 1.4M
- FWONA 62.4K
- Earning Date
- BIIB 10-29-2025
- FWONA 08-07-2025
- Dividend Yield
- BIIB N/A
- FWONA N/A
- EPS Growth
- BIIB 31.67
- FWONA N/A
- EPS
- BIIB 10.45
- FWONA 1.07
- Revenue
- BIIB $9,997,000,000.00
- FWONA $3,866,000,000.00
- Revenue This Year
- BIIB $2.00
- FWONA $20.50
- Revenue Next Year
- BIIB N/A
- FWONA $11.45
- P/E Ratio
- BIIB $12.64
- FWONA $84.49
- Revenue Growth
- BIIB 3.36
- FWONA 4.71
- 52 Week Low
- BIIB $110.04
- FWONA $68.00
- 52 Week High
- BIIB $206.70
- FWONA $96.40
- Technical
- Relative Strength Index (RSI)
- BIIB 46.86
- FWONA 49.73
- Support Level
- BIIB $135.22
- FWONA $88.67
- Resistance Level
- BIIB $138.50
- FWONA $92.54
- Average True Range (ATR)
- BIIB 3.37
- FWONA 1.59
- MACD
- BIIB -0.47
- FWONA 0.20
- Stochastic Oscillator
- BIIB 28.22
- FWONA 66.20
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FWONA Liberty Media Corporation Series A Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.